Clare Proudfoot

832 total citations
36 papers, 558 citations indexed

About

Clare Proudfoot is a scholar working on Cardiology and Cardiovascular Medicine, Rheumatology and Immunology. According to data from OpenAlex, Clare Proudfoot has authored 36 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 11 papers in Rheumatology and 10 papers in Immunology. Recurrent topics in Clare Proudfoot's work include Heart Failure Treatment and Management (13 papers), Rheumatoid Arthritis Research and Therapies (11 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). Clare Proudfoot is often cited by papers focused on Heart Failure Treatment and Management (13 papers), Rheumatoid Arthritis Research and Therapies (11 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). Clare Proudfoot collaborates with scholars based in United Kingdom, Switzerland and United States. Clare Proudfoot's co-authors include Daniel L. Jackson, Kimberley Cann, Timothy Walsh, Stefano Corda, Rachel Studer, Chieh-I Chen, Andreas Kuznik, Raquel Lahoz, Shraddha Shinde and Erin Mangan and has published in prestigious journals such as Circulation, Kidney International and Journal of the American Society of Nephrology.

In The Last Decade

Clare Proudfoot

35 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clare Proudfoot United Kingdom	13	178	177	141	131	66	36	558
Chia‐Chen Teng United States	13	104 0.6×	76 0.4×	67 0.5×	151 1.2×	44 0.7×	43	497
Maureen A. Seckel United States	12	89 0.5×	74 0.4×	50 0.4×	126 1.0×	20 0.3×	41	469
Brigid C. Flynn United States	14	137 0.8×	217 1.2×	77 0.5×	41 0.3×	31 0.5×	60	638
Bilsel Baç Türkiye	10	189 1.1×	27 0.2×	146 1.0×	34 0.3×	23 0.3×	18	498
Rita Champaneria United Kingdom	18	74 0.4×	113 0.6×	90 0.6×	122 0.9×	13 0.2×	35	1.2k
Marion Pépin France	10	107 0.6×	124 0.7×	70 0.5×	2 0.0×	46 0.7×	35	418
Caroline A. Kim United States	7	102 0.6×	214 1.2×	49 0.3×	23 0.2×	7 0.1×	7	454
Anna Batchelor United Kingdom	7	50 0.3×	105 0.6×	29 0.2×	7 0.1×	19 0.3×	12	552
Rambod Amirnovin United States	7	125 0.7×	557 3.1×	37 0.3×	10 0.1×	3 0.0×	12	791
Jenkinson United Kingdom	5	69 0.4×	30 0.2×	15 0.1×	8 0.1×	156 2.4×	6	466

Countries citing papers authored by Clare Proudfoot

Since Specialization

Citations

This map shows the geographic impact of Clare Proudfoot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clare Proudfoot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clare Proudfoot more than expected).

Fields of papers citing papers by Clare Proudfoot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clare Proudfoot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clare Proudfoot. The network helps show where Clare Proudfoot may publish in the future.

Co-authorship network of co-authors of Clare Proudfoot

This figure shows the co-authorship network connecting the top 25 collaborators of Clare Proudfoot. A scholar is included among the top collaborators of Clare Proudfoot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clare Proudfoot. Clare Proudfoot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sinha, Smeeta, et al.. (2025). Treatment and Disease Burden in Patients with Complement 3 Glomerulopathy: Multinational Real-World Study Results. PubMed. 5(1). 380–394.

Lafayette, Richard, et al.. (2023). C3 Glomerulopathy Current Treatment Options and Real-World Management: Results from a Multi-Country Study. Journal of the American Society of Nephrology. 34(11S). 984–984. 1 indexed citations

Lafayette, Richard, et al.. (2023). Persistence of Signs and Symptoms in Treated Patients with C3 Glomerulopathy (C3G): Evidence from Real-World Data. Journal of the American Society of Nephrology. 34(11S). 272–272. 1 indexed citations

Proudfoot, Clare, et al.. (2022). Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review. The European Journal of Health Economics. 24(3). 453–467. 6 indexed citations

Schlienger, Raymond G., et al.. (2022). Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study. Cardiology and Therapy. 11(1). 113–127. 8 indexed citations

Lahoz, Raquel, Clare Proudfoot, Stefano Corda, et al.. (2021). Caregivers of Patients with Heart Failure: Burden and the Determinants of Health-Related Quality of Life. Patient Preference and Adherence. Volume 15. 1153–1164. 30 indexed citations

Proudfoot, Clare, et al.. (2021). Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review. International Journal of Cardiology. 331. 164–171. 35 indexed citations

Lahoz, Raquel, Clare Proudfoot, Stefano Corda, et al.. (2021). Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study. Patient Preference and Adherence. Volume 15. 1693–1706. 13 indexed citations

Proudfoot, Clare, Raquel Lahoz, Stefano Corda, et al.. (2020). Patients with heart failure and a LVEF less than 40% present an overall lower health related quality of life than those with LVEF between 40% and 60%: a multinational real-world survey in EU. European Heart Journal. 41(Supplement_2). 2 indexed citations

10.

Gossec, Laure, Vibeke Strand, Clare Proudfoot, et al.. (2019). Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. The Journal of Rheumatology. 46(10). 1259–1267. 10 indexed citations

11.

Muszbek, N., Clare Proudfoot, Marie Fournier, et al.. (2019). Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. Advances in Therapy. 36(6). 1337–1357. 10 indexed citations

12.

Proudfoot, Clare, et al.. (2019). PCV87 A REVIEW ASSESSING THE PROPORTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS AMONGST HEART FAILURE PATIENTS. Value in Health. 22. S557–S557. 1 indexed citations

13.

Choy, Ernest, Nick Freemantle, Clare Proudfoot, et al.. (2019). Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs. Advances in Therapy. 36(4). 817–827. 6 indexed citations

14.

Fournier, Marie, Chieh-I Chen, Andreas Kuznik, et al.. (2019). <p>Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient</p>. ClinicoEconomics and Outcomes Research. Volume 11. 117–128. 7 indexed citations

15.

Munakata, Julie, Wenhui Wei, Clare Proudfoot, et al.. (2018). Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. ClinicoEconomics and Outcomes Research. Volume 10. 805–819. 3 indexed citations

16.

Proudfoot, Clare, Peter Ackerman, Cyril Llamoso, et al.. (2018). 547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir. Open Forum Infectious Diseases. 5(suppl_1). S203–S203. 1 indexed citations

17.

Strand, Vibeke, Laure Gossec, Clare Proudfoot, et al.. (2018). Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Research & Therapy. 20(1). 129–129. 26 indexed citations

18.

Chastek, Benjamin, Chieh-I Chen, Clare Proudfoot, et al.. (2017). Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. Advances in Therapy. 34(11). 2422–2435. 33 indexed citations

19.

Proudfoot, Clare. (2012). PCN143 Utility Data in Appraisals of Oncology Drugs by the UK National Institute for Health and Clinical Excellence. Value in Health. 15(7). A435–A436. 2 indexed citations

20.

Jackson, Daniel L., Clare Proudfoot, Kimberley Cann, & Timothy Walsh. (2009). The incidence of sub-optimal sedation in the ICU: a systematic review. Critical Care. 13(6). R204–R204. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact